Cargando…

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

BACKGROUND: Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (⩾30 months) were investigated in sunitinib-treated patients with metastatic renal cell carcinoma (RCC). METHODS: Data were pooled from 1059 patients in six trials. Baseline variables, includi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Motzer, R J, Escudier, B, Bukowski, R, Rini, B I, Hutson, T E, Barrios, C H, Lin, X, Fly, K, Matczak, E, Gore, M E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694236/ https://www.ncbi.nlm.nih.gov/pubmed/23695024 http://dx.doi.org/10.1038/bjc.2013.236

Ejemplares similares

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
por: Gore, M E, et al.
Publicado: (2015)

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
por: Rini, Brian I., et al.
Publicado: (2011)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
por: Patil, S, et al.
Publicado: (2012)

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
por: Blagoev, Krastan B., et al.
Publicado: (2013)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G, et al.
Publicado: (2010)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
por: Donskov, Frede, et al.
Publicado: (2015)

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
por: Bamias, A, et al.
Publicado: (2013)

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
por: Harmon, Charles S., et al.
Publicado: (2013)

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
por: DePrimo, Samuel E, et al.
Publicado: (2007)

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma
por: Cella, David, et al.
Publicado: (2014)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
por: Bracarda, S, et al.
Publicado: (2012)

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2022)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
por: Haanen, J.B.A.G., et al.
Publicado: (2023)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J J, et al.
Publicado: (2018)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J. J., et al.
Publicado: (2017)

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G H J, et al.
Publicado: (2010)

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
por: Staehler, M, et al.
Publicado: (2018)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
por: Escudier, B, et al.
Publicado: (2014)

Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
por: Vasileiadis, Theofanis, et al.
Publicado: (2019)

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
por: Gu, Cheng-Yuan, et al.
Publicado: (2021)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Characterization of the novel In1059 harbouring VIM gene cassette
por: Wang, Dongguo, et al.
Publicado: (2017)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
por: Mohammad, H., et al.
Publicado: (2021)

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2014)

Corrigendum: The distribution and behavioral characteristics of plateau pikas (Ochotonacurzoniae). ZooKeys 1059: 157–171. https://doi.org/10.3897/zookeys.1059.63581
por: Qiu, Jun, et al.
Publicado: (2022)

Clinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinoma
por: Bourlon, Maria T., et al.
Publicado: (2016)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
por: Choueiri, T.K., et al.
Publicado: (2021)

Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
por: Buda-Nowak, Anna, et al.
Publicado: (2017)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
por: Beuselinck, B, et al.
Publicado: (2013)

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
por: Billemont, B, et al.
Publicado: (2008)

Oboenkonzerte BWV 1053, BWV 1059, BWV 1055 Oboe concertos = Concertos pour hautbois /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_5selidron1q368dehb00n73hnm